Experts emphasize recording smoking status in cancer trials to improve treatment efficacy, survival, and outcomes, urging ...

Since 2014, research has increasingly shown that continued tobacco use negatively impacts patients receiving surgery, ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 1/1b study titled ‘A ...

Introduction: Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, ...

Findings from this phase 2 trial support further study of erlotinib as "an effective, acceptable cancer preventive agent for FAP-associated gastrointestinal polyposis," the study team says.

The addition of bevacizumab to erlotinib did not demonstrated improvement in overall survival in patients with EGFR-mutant non–small cell lung cancer treated in a phase 3 study.

The combination of erlotinib (Tarceva) and ramucirumab (Cyramza) showed better progression-free survival (PFS) in patients with newly diagnosedEGFR-mutant metastatic non small cell lung cancer (NSCLC) ...

Adjuvant erlotinib improved 2-year disease-free survival in patients with EGFR mutation-positive stage IIIA NSCLC compared with chemotherapy, with a better tolerability profile. This study suggests ...

Cabozantinib monotherapy or in combination with erlotinib may be superior to erlotinib alone for progression-free survival.